GeoVax Shows New Data from Zika Vaccine

GeoVax Labs (OTCQB:GOVX) presented its research on the effectiveness of their Zika vaccine protection with mice.
As quoted in the press release:

This is the first report of i) a Zika vaccine based on the ZIKV NS1 protein, and ii) single-dose protection against ZIKV using an immunocompetent lethal mouse challenge model.
Details of the study were presented on June 4 by Farshad Guirakhoo, PhD, GeoVax’s Chief Scientific Officer, at the American Society for Microbiology (ASM) Microbe conference in New Orleans. ASM Microbe 2017 showcases the best microbial sciences in the world including seven tracks, 500+ sessions and 575+ speakers from 96 countries covering topics from basic science to translation and application.
The vaccine was tested at the Centers for Disease Control and Prevention (CDC) in Ft. Collins, Colorado with funding by a grant from the CDC. In the study, outbred immunocompetent mice were exposed to a lethal challenge dose of ZIKV delivered directly into the brain. A single dose of GeoVax’s NS1 vaccine candidate protected 100% of vaccinated animals. In contrast, 80-90% of sham-immunized control animals died within 7-10 days.

Click here to read the full press release.